News
A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.
The Trump administration is exploring a five-year pilot program to include weight-loss drugs like Wegovy, Ozempic, Zepbound, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results